Remove 2025 Remove Diabetes Remove Pharmaceutical Manufacturing
article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Packaging 111
article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

Additionally, in October, EPR shared Phase III trial data for the type 1 diabetes treatment TZIELD (Teplizumab), which suggested that the medicine could slow disease progression. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry.

article thumbnail

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

pharmaphorum

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. A respiratory platform similar to the diabetes one, the Digital Health Solution is yet another future-looking inclusion in the Chiesi plan.